Nhs north west london integrated formulary changes 14.11.13 v8.xlsx

North West London Integrated Formulary
updates and changes included in version 8.0 See BNF for circumstances under which this can be prescribed on the NHS.
Will be available generically sooner than similar drugs.
Changes to 'initiate by specialist only?' entries
Corrections and clarifications
remove the annotation ‘second line osmotic laxative’ Not for HRT. For use in line with NICE’s TA guidance 161 on secondary prevention of osteoporotic fragility fracture in The NWLIF New Drugs Panel has not to date received a request to support tadalafil use for treatment of the signs and symptoms of benign prostactic hyperplasia, so it not included in the Formulary for this 7.4 Tadalafil tablets 2.5mg, 5mg, 10mg, 20mg.
GPs should not be asked to prescribe methotrexate for treatment of 8.1 and 10.1 Methotrexate 2.5mg and 10mg tablets remove references to first line as a soap subsitute only.
North West London Integrated Formulary
updates and changes included in version 7.0 Lixisenatide, 50 micrograms/mL, 10 micrograms/dose prefilled pen. 100 micrograms/mL, 20 micrograms/dose prefilled pen. treatment initiation pack, 10 micrograms/dose prefilled pen and 20 11.6 Timolol unit dose eye gel 0.1% - preservative free 13.4 Hydrocortisone 2.5% ointment and cream Changes to 'initiate by specialist only?' entries
Corrections
North West London Integrated Formulary
updates and changes included in version 6.0 Anticoagulant choice where the indication is prophylaxis of stroke and systemic embolism in atrial-fibrillation - the following CCGs prefer the 'which anticoagulant?' discussion recommended by NICE to take place outside the hospital. Central London CCG, Ealing CCG, Hammersmith and Fulham CCG, Harrow CCG, Hounslow CCG. Flutiform aerosol inhalers. Aerosol inhalation 50 and 125 (aerosol containing 5mcg formoterol plus 50/125 mcg fluticasone/metered inhalation. Aerosol inhalation 250 (aerosol containing 10mcg 3.2 formoterol plus 250 mcg fluticasone/metered inhalation) 4.8 Perampanel, 2mg, 4mg,6mg, 8mg, 10mg, 12mg tablets Agreed to be added for use in line with NICE FAD, 17th May 2013. Mirabegron is recommended as an option for treating the symptoms of overactive bladder only for people in whom antimuscarinic drugs are contraindicated or clinically ineffective, or have unacceptable side Bimatoprost 300micrograms/ml eye drops, 300micrograms/ml Added in addition to 100microgram/ml eye drops.
11.6 Latanoprost 50micrograms/ml preservative free single use drops 11.4 Sodium cromoglycate 2% preservative free single use drops Accrete D3® tablets, calcium carbonate 1.5g (calcium 9.6 600mg/15mmol), colecalciferol 10 micrograms (400 units) Scheriproct Ointment, cinchocaine (dibucaine) hydrochloride 0.5%, Sodium Valproate crushable tablets 100mg, liquid (sugar-free) 200mg 9.6 Colecalciferol, (Cholecalciferol, vitamin D3) Desunin 800unit tablets Capsules are a licensed medicine. Soluble tablets are a food supplement. Soluble tablets are an option for patients with swallowing ProductPrednisolone retention enema, long tube, 20mg in 100ml (as sodium C lcitonin (salmon) /salcatonin, nasal spray 7.3 Etynodiol diacetate 500microgram tablets (Femulen) Vitamin B compound, tablets containing nicotinamide 15mg, riboflavin 9.6 1mg and thiamine hydrochloride 1mg.
Lassar's Paste (Zinc and Salicylic Acid Paste), paste Zinc oxide 24%, 13.5 salicylic acid 2%, starch 24%, white soft paraffin 50% Changes to 'initiate by specialist only?' entries
Corrections
11.6 Xalacom entry amended to latanoprost and timolol eye drops Fluticasone furoate and fluticasone propionate nasal spray entries NHS North West London Integrated Formulary
updates and changes included in version 5.0 2.12 Tredaptive (MR tablets nicotinic acid 1g + laropiprant 20mg). Changes to 'initiate by specialist only?' entries
Changes to comments
NHS North West London Integrated Formulary
updates and changes included in version 4.0 Prescribe by brand. The delivery characteristics of oral mesalazine preparations may vary and they should not be considered interchangeable. Octasa is the lowest cost brand and should be prescribed instead of other brands for new who require a change to their drug regimen. Discretion should be applied in switching patients to Octasa who have mild and/or stable UC.
Mezavant XL should only be considered for select patients experiencing difficultly with a high pill burden (i.e. >2.4g/daily), since it has a convenient once-daily dosing advantage. Since Mezavant XL is almost twice the cost of Octasa, at the point of maintenance dose prescribing (i.e. ≤2.4g/daily), Octasa should be substituted. 1.5 Mesalazine MR tablets 400mg, 800mg (Octasa) As per licensed indication, in adults for the prevention of skeletal events in patients with breast cancer and bone metastases. 1.5 Mesalazine MR tablets 400mg (Mesren MR) 7.2 Estradiol vaginal tablets 25micrograms (Vagifem) 6.4 Testosterone patch for women, (intrinsa) Changes to 'initiate by specialist only?' entries
Changes to comments
Added marked in red
3rd line treatment in patients with refractory angina where re-vascularisation is not appropriate and who continue to suffer from angina despite otherwise maximum anti-angina treatment or for patients unable to tolerate or with a contraindication to beta-blocker or an appropriate calcium channel blocker. In line with NICE guidance TA267 NHS North West London Integrated Formulary
updates and changes included in version 3.0a.
Anticoagulant choice where the indication is prophylaxis of stroke and systemic embolism in atrial-fibrillation - the following CCGs prefer the 'which anticoagulant?' discussion recommended by NICE to take place outside the hospital. Central London CCG, Ealing CCG, Hammersmith and Fulham CC 2.8 Dabigatran etexilate capules, 110mg, 150mg Anticoagulant choice where the indication is prophylaxis of stroke and systemic embolism in atrial-fibrillation - the following CCGs prefer the 'which anticoagulant?' discussion recommended by NICE to take place outside the hospital. Central London CCG, Ealing CCG, Hammersmith and Fulham CCG, Harrow CCG, Hounslow CCG. Adrenaline / epinephrine auto-injectors. Jext 150micrograms, Included in the IF for restricted use: it should be initiated in secondary Tapentadol tablets 50mg, 75mg; MR tablets 50mg, 100mg, 150mg, care and only used in line with the protocol approved by that hospital's 4.7 Tramadol MR capsules, 50mg, 100mg, 150mg, 200mg 7.3 Ethinyloestradiol + norelgestromin transdermal patch (Evra) 5.3 Oseltamivir oral suspension 60mg/5ml (discontinued) Changes to 'initiate by specialist only?' entries
Changes to comments
NHS North West London Integrated Formulary
updates and changes included in version 2.0 4.1 Chlordiazepoxide capsules 5mg, 10mg.
4.1 Zolpidem 5mg (10mg was already included) Pipotiazine palmitate depot inj 100mg/ml (the product is 50mg/ml 4.7 Morphine (Morphgesic SR) 15mg, 90mg (discont) 5.1 Erythromycin tabs 500mg (only available as stearate) 6.3 Betamethasone tablets 500micrograms (soluble tabs remain) 11.8 Ciclosporin eye drops and ointment (unlicensed specials) 13.8 Sunsense Daily SPF 60+ (not available) Changes to 'initiate by specialist only?' entries
Changes to comments
Minor changes to the entry in the comments column Remove acne treatment order 'first choice' etc. Strengths specified (200 & 400 micrograms/inhalation) 15.1 Alfentanil injection 500micrograms/ml First choice' becomes 'first line' throughout. Comment on specialist initiation added to page 1 A number of brand names that are not needed on prescriptions have been removed.

Source: http://www.northwestlondon.nhs.uk/_uploads/~filestore/EB2AFBAD-EDBB-42EE-9D33-488DD86D2B5C/north-west-london-integrated-formulary-cumulative-changes-14-11.pdf

June 2009 p&t minutes 7.23.09 final.web.xls

AmeriChoice Pharmacy & Therapeutics Committee Minutes June 17, 2009 Meeting Date: June 17, 2009 Location: Via conference call D. Morgan, J. Bellicini, R. Brekosky, J.Weiss, R. Justman, S. Nichols, C. Freed, M. Mahler, S. Stein, E. Francis, B. Selius, A. Burkins, M. Reich, J. Carlson, V. Members in Attendance: Members Absent: J. Hancovsky, S. Bush, G. Fleszar, D. Rose, K. Top

F06_ion

The nuclear renaissance – technologies and challenges It is rare that we all seem to agree on any-“double jeopardy” – whereby a plant canthing these days, but one thing few peoplebe built but still not be allowed to operatedisagree with is that global demand for en-– are prohibitive barriers to potential in-ergy in general – and electricity in partic-ular – is set to rise s

© 2008-2018 Medical News